AlphaQuest LLC Buys 25,282 Shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)

AlphaQuest LLC grew its holdings in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) by 800.1% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 28,442 shares of the biotechnology company’s stock after purchasing an additional 25,282 shares during the quarter. AlphaQuest LLC’s holdings in BioCryst Pharmaceuticals were worth $214,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds also recently bought and sold shares of BCRX. Venturi Wealth Management LLC acquired a new position in BioCryst Pharmaceuticals in the fourth quarter worth $46,000. R Squared Ltd acquired a new position in BioCryst Pharmaceuticals in the fourth quarter worth $48,000. KBC Group NV boosted its stake in BioCryst Pharmaceuticals by 80.1% in the fourth quarter. KBC Group NV now owns 10,198 shares of the biotechnology company’s stock worth $77,000 after purchasing an additional 4,537 shares in the last quarter. Raymond James Financial Inc. acquired a new position in BioCryst Pharmaceuticals in the fourth quarter worth $80,000. Finally, Quantinno Capital Management LP acquired a new position in BioCryst Pharmaceuticals in the third quarter worth $82,000. Institutional investors and hedge funds own 85.88% of the company’s stock.

Analyst Ratings Changes

A number of research firms have commented on BCRX. Evercore ISI boosted their price objective on BioCryst Pharmaceuticals from $10.00 to $12.00 and gave the stock an “outperform” rating in a research note on Monday, January 13th. Wedbush initiated coverage on BioCryst Pharmaceuticals in a research note on Tuesday, February 25th. They set an “outperform” rating and a $15.00 price target on the stock. Needham & Company LLC upped their price target on BioCryst Pharmaceuticals from $14.00 to $15.00 and gave the company a “buy” rating in a research note on Monday, January 13th. HC Wainwright reaffirmed a “buy” rating and set a $30.00 price target on shares of BioCryst Pharmaceuticals in a research note on Tuesday, February 25th. Finally, Royal Bank of Canada reaffirmed an “outperform” rating and set a $11.00 price target (up previously from $10.00) on shares of BioCryst Pharmaceuticals in a research note on Tuesday, February 25th. One research analyst has rated the stock with a hold rating and seven have given a buy rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $15.57.

BioCryst Pharmaceuticals Stock Performance

Shares of NASDAQ BCRX opened at $7.70 on Monday. The stock has a market cap of $1.61 billion, a P/E ratio of -12.62 and a beta of 1.85. The firm has a 50 day moving average price of $8.14 and a 200 day moving average price of $7.85. BioCryst Pharmaceuticals, Inc. has a 52-week low of $4.03 and a 52-week high of $9.50.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last issued its quarterly earnings data on Monday, February 24th. The biotechnology company reported ($0.13) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.07) by ($0.06). The company had revenue of $131.50 million for the quarter, compared to analysts’ expectations of $126.64 million. The business’s revenue for the quarter was up 40.8% on a year-over-year basis. During the same period in the prior year, the company posted $0.28 EPS. Analysts predict that BioCryst Pharmaceuticals, Inc. will post -0.36 earnings per share for the current fiscal year.

BioCryst Pharmaceuticals Company Profile

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.